by Peter Ruf, and Horst Lindhofer

Slides:



Advertisements
Similar presentations
Molecular Therapy - Methods & Clinical Development
Advertisements

Volume 10, Issue 2, Pages (August 2004)
An anti-CD20–IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma by Stephen D. Gillies, Yan Lan, Steven Williams,
Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man  Immunity 
Volume 5, Issue 1, Pages (January 2009)
Downregulation of Antigen-Presenting Cell Functions After Administration of Mitogenic Anti-CD3 Monoclonal Antibodies in Mice by Eric Muraille, Fabienne.
Heat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice by Robert G. Newman,
Peptide Immunization Indicates that CD8+ T Cells are the Dominant Effector Cells in Trinitrophenyl-Specific Contact Hypersensitivity  Stefan Martin, Michael.
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers by Andrea.
Sequential production of interferon-γ by NK1
by Rafijul Bari, Teresa Bell, Wai-Hang Leung, Queenie P
Complexes of trophoblastic peptides and heat shock protein 70 as a novel contraceptive vaccine in a mouse model  Mei Han, Yuan Yao, Wangjiang Zeng, Yanfang.
Antigen-Specific CD8 T Cells Can Eliminate Antigen-Bearing Keratinocytes with Clonogenic Potential via an IFN-γ-Dependent Mechanism  Rachel L. De Kluyver,
Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine  Weiqing Jing,
Differentiation and Functions of CD8+ Effector T Cells
by Yoshinobu Maeda, Pavan Reddy, Kathleen P
Volume 15, Issue 2, Pages (February 2007)
Nonhemolytic antigen loss from red blood cells requires cooperative binding of multiple antibodies recognizing different epitopes by James C. Zimring,
by Clemens B. Caspar, Shoshana Levy, and Ronald Levy
by Norman Nausch, Ioanna E
Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells by Wuding Zhou, Hetal Patel, Ke Li, Qi Peng, Marie-Bernadette.
LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice  Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.
by Éric Aubin, Réal Lemieux, and Renée Bazin
The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease by Shan He, Fang.
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy by Fumihiko Tsushima, Sheng Yao, Tahiro Shin, Andrew Flies, Sarah.
Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies.
by Sheng F. Cai, Xuefang Cao, Anjum Hassan, Todd A
Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity by Mikael Maksimow, Mari.
by Jamie Honeychurch, Alison L. Tutt, Thomas Valerius, Ingmar A. F. M
Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies by Katrin U. Lundin, Peter O.
by Cunren Liu, Shaohua Yu, John Kappes, Jianhua Wang, William E
by Bindu Varghese, Adam Widman, James Do, Behnaz Taidi, Debra K
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.
Volume 42, Issue 2, Pages (February 2015)
Volume 18, Issue 5, Pages (May 2003)
Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses  William H.D. Hallett, Erik Ames, Maite.
Xinchun Chen, Yi Zeng, Gang Li, Nicolas Larmonier, Michael W
Volume 6, Issue 4, Pages (April 1997)
Volume 13, Issue 1, Pages (January 2006)
Volume 17, Issue 10, Pages (December 2016)
Volume 19, Issue 3, Pages (March 2011)
Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells 
Endogenous polyclonal anti–IL-1 antibody responses potentiate IL-1 activity during pathogenic inflammation  Gunther Spohn, PhD, Natalia Arenas-Ramirez,
Arming Cytokine-induced Killer Cells With Chimeric Antigen Receptors: CD28 Outperforms Combined CD28–OX40 “Super-stimulation”  Andreas A Hombach, Gunter.
Topical Imiquimod Treatment Prevents UV-Light Induced Loss of Contact Hypersensitivity and Immune Tolerance  Thomas H. Thatcher, Irina Luzina, Rita Fishelevich,
Stanford L Peng, Andrea J Gerth, Ann M Ranger, Laurie H Glimcher 
Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen- Specific Regulatory T Cells  Dan Blat, Ehud Zigmond, Zoya Alteber,
Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.
by Frank M. Szaba, and Stephen T. Smiley
Volume 21, Issue 1, Pages (January 2013)
Volume 12, Issue 5, Pages (November 2005)
Volume 5, Issue 1, Pages (January 2009)
by Derek Hoi-Hang Ho, and Roger Hoi-Fung Wong
Volume 119, Issue 1, Pages (July 2000)
CTLA-4 Regulates Induction of Anergy In Vivo
Volume 20, Issue 5, Pages (May 2012)
IL-12 affects Dermatophagoides farinae–induced IL-4 production by T cells from pediatric patients with mite-sensitive asthma  Takeshi Noma, MD, PhD, Izumi.
Volume 16, Issue 4, Pages (April 2002)
In Vivo Expansion of Regulatory T cells With IL-2/IL-2 mAb Complexes Prevents Anti- factor VIII Immune Responses in Hemophilia A Mice Treated With Factor.
Volume 17, Issue 5, Pages (May 2009)
Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response  Arup Garu, Gopikrishna.
Volume 20, Issue 4, Pages (April 2012)
Interleukin-10-Treated Dendritic Cells Modulate Immune Responses of Naive and Sensitized T Cells In Vivo  Gabriele Müller, Anke Müller  Journal of Investigative.
Dissecting the Multifactorial Causes of Immunodominance in Class I–Restricted T Cell Responses to Viruses  Weisan Chen, Luis C. Antón, Jack R. Bennink,
Volume 2, Issue 4, Pages (October 2002)
Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection by Maria Moeller, Nicole M. Haynes, Michael.
Loss of Transgene following ex vivo Gene Transfer is Associated with a Dominant Th2 Response: Implications for Cutaneous Gene Therapy  Zhenmei Lu, Soosan.
Volume 19, Issue 4, Pages (October 2003)
Pretreatment of donor T cells with a c-Rel antagonist does not impair GVT activity. Pretreatment of donor T cells with a c-Rel antagonist does not impair.
UV Exposure Boosts Transcutaneous Immunization and Improves Tumor Immunity: Cytotoxic T-Cell Priming through the Skin  Pamela Stein, Gerd Rechtsteiner,
Presentation transcript:

by Peter Ruf, and Horst Lindhofer Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody by Peter Ruf, and Horst Lindhofer Blood Volume 98(8):2526-2534 October 15, 2001 ©2001 by American Society of Hematology

BsAb-mediated cytotoxicity in vitro BsAb-mediated cytotoxicity in vitro.Tumor cell killing was measured by a colorimetric MTT-based assay. BsAb-mediated cytotoxicity in vitro.Tumor cell killing was measured by a colorimetric MTT-based assay. (A) Varying E/T ratios were carried out with a constant amount of 50 ng/mL bsAb BiLu (▪) or bsF(ab′)2 (▵) targeted against transfected B16-EpCAM cells. To differentiate antigen-independent cell lysis by the bsAb, nontransfected B16 target cells were used (bsAb wild-type, ■). (B) At an E/T ratio of 20:1, the bsAb BiLu (▪) and bsF(ab′)2 (▵) were titrated from 50 to 0.05 ng/mL. Controls with the parental antibodies were performed at equimolar amounts (17A2+C215, *; and C215, ○). B16-EpCAM cells were used as targets. Effector cell-induced background lysis in the absence of antibody was subtracted. Peter Ruf, and Horst Lindhofer Blood 2001;98:2526-2534 ©2001 by American Society of Hematology

The bsAb BiLu reveals high antitumor activity in vivo in 2 different syngeneic tumor models.(A) C57BL/6 mice (n = 6) received 5 × 103B16-EpCAM cells intraperitoneally on day 0. The bsAb BiLu reveals high antitumor activity in vivo in 2 different syngeneic tumor models.(A) C57BL/6 mice (n = 6) received 5 × 103B16-EpCAM cells intraperitoneally on day 0. BsAb treatment was started with 2.5 μg on day 2 and continued with 1 μg each on days 4 and 7 (▪). The group that received parental antibodies (▿) (n = 6) was treated with a combination of the 2 monospecific antibodies C215 (antihuman EpCAM) and 17A2 (antimurine CD3). The control group (+) (n = 6) received no antibody. To clarify the antigen dependency of the treatment one group of mice (■) (n = 6) was challenged with 5 × 103 untransfected B16 cells and injected with bsAb as indicated above. Experiments were repeated 3 times with similar results. (B) BALB/c mice were challenged with 2 × 106A20-EpCAM cells intravenously followed by intraperitoneal injection of 4 μg bsAb (▪) (n = 12) or bsF(ab′)2 (♦) (n = 8) 3 hours later. Again, a control group with parental antibodies (▿) (n = 7) was included, and data were confirmed by another independent experiment. Peter Ruf, and Horst Lindhofer Blood 2001;98:2526-2534 ©2001 by American Society of Hematology

BsAb-treated mice develop long-lasting antitumor protection BsAb-treated mice develop long-lasting antitumor protection.The survival of mice is shown after donation of 5 × 103B16-EpCAM cells intraperitoneally on day 0 followed by the application of 10 μg bsAb BiLu (▪) on day 2 and another 5 μg on days 4 and 7. BsAb-treated mice develop long-lasting antitumor protection.The survival of mice is shown after donation of 5 × 103B16-EpCAM cells intraperitoneally on day 0 followed by the application of 10 μg bsAb BiLu (▪) on day 2 and another 5 μg on days 4 and 7. The control group received no antibody (+). Mice surviving the first tumor challenge (14 of 18 mice) were rechallenged on day 144 with a minimal lethal dose of 750 B16-EpCAM cells intraperitoneally. This time no bsAb treatment was performed. Whereas all control mice (n = 5) developed a tumor (not shown), mice pretreated with the bsAb BiLu successfully rejected the second tumor challenge. The experiment was repeated twice with similar results. Peter Ruf, and Horst Lindhofer Blood 2001;98:2526-2534 ©2001 by American Society of Hematology

Immunization scheme of BALB/c mice Immunization scheme of BALB/c mice.Mice were immunized with 4 μg bsAb BiLu followed by 5 × 104 irradiated A20-EpCAM cells given intraperitoneally 2 hours later. Immunization scheme of BALB/c mice.Mice were immunized with 4 μg bsAb BiLu followed by 5 × 104 irradiated A20-EpCAM cells given intraperitoneally 2 hours later. Then, after 4 weeks an identical booster immunization was performed, and finally mice were intraperitoneally challenged another 2 weeks later with 7 × 105 A20 wild-type cells. The role of the T cells was investigated by antibody-induced depletion of CD4+ or CD8+ T cells with 400 to 750 μg CD4.2 antibody and 500 μg CD8.2 antibody, respectively, at indicated time points. From all mice blood samples were collected before any treatment (control sera) as well as 2 days before tumor challenge. Peter Ruf, and Horst Lindhofer Blood 2001;98:2526-2534 ©2001 by American Society of Hematology

BALB/c mice immunized with intact bsAb BiLu and irradiated A20-EpCAM cells successfully reject A20 wild-type challenge.Mice were immunized as indicated in Figure 4 with bsAb (▪) or bsF(ab′)2 fragments (♦) and irradiated A20-EpCAM cells. BALB/c mice immunized with intact bsAb BiLu and irradiated A20-EpCAM cells successfully reject A20 wild-type challenge.Mice were immunized as indicated in Figure 4 with bsAb (▪) or bsF(ab′)2 fragments (♦) and irradiated A20-EpCAM cells. The control group was treated only with irradiated tumor cells without bsAb (+). The CD4 depletion group (■) was identically treated to the bsAb group but injected with CD4+ T-cell–depleting CD4.2 antibody. In 2 independent experiments similar data were obtained. Peter Ruf, and Horst Lindhofer Blood 2001;98:2526-2534 ©2001 by American Society of Hematology

Antibodies directed against the A20 immunoglobulin Id could be detected in sera of BALB/c mice immunized with intact bsAb BiLu and A20-EpCAM cells.This response was clearly diminished after depletion of CD4+ T cells in the immunization phase. Antibodies directed against the A20 immunoglobulin Id could be detected in sera of BALB/c mice immunized with intact bsAb BiLu and A20-EpCAM cells.This response was clearly diminished after depletion of CD4+ T cells in the immunization phase. The use of A20 wild-type cells and intact bsAb resulted in a weak reaction, too. For the anti-idiotypic ELISA pooled and serially diluted preimmune or immune sera were incubated on A20 Id-coated ELISA plates, followed by biotin-labeled goat antimouse IgG1 and developed with avidin-peroxidase. Preimmune sera revealed no reaction. Peter Ruf, and Horst Lindhofer Blood 2001;98:2526-2534 ©2001 by American Society of Hematology

Specific versus nonspecific immunization Specific versus nonspecific immunization.To differentiate between target-antigen–dependent and –independent immunization effects induced by the bsAb BiLu, mice were immunized as outlined in Figure 4 with bsAb and irradiated A20-EpCAM cells (▪), or with bsAb... Specific versus nonspecific immunization.To differentiate between target-antigen–dependent and –independent immunization effects induced by the bsAb BiLu, mice were immunized as outlined in Figure 4 with bsAb and irradiated A20-EpCAM cells (▪), or with bsAb and nontransfected A20 wild-type cells (■). Only the use of A20-EpCAM cells resulted in full tumor protection. Control mice (+) that received irradiated A20 wild-type cells without bsAb revealed no protection. Each group comprised 6 mice. Peter Ruf, and Horst Lindhofer Blood 2001;98:2526-2534 ©2001 by American Society of Hematology

Adoptive transfer of immune serum into naive BALB/c mice significantly delays tumor growth (P = .018).Sera taken from mice 6 weeks after immunization with bsAb BiLu (▪) and irradiated tumor cells were pooled and transferred (300 μL) together with 3 × 105 vi... Adoptive transfer of immune serum into naive BALB/c mice significantly delays tumor growth (P = .018).Sera taken from mice 6 weeks after immunization with bsAb BiLu (▪) and irradiated tumor cells were pooled and transferred (300 μL) together with 3 × 105 viable A20 cells intravenously into naive BALB/c mice. The control group (+) received serum of naive, untreated mice in combination with tumor cells. Peter Ruf, and Horst Lindhofer Blood 2001;98:2526-2534 ©2001 by American Society of Hematology

The depletion of CD8+ T cells in the effector phase reduces tumor protection.Moreover, depletion of CD4+ T cells in the priming phase results in a significant loss of tumor rejection (P = .02). The depletion of CD8+ T cells in the effector phase reduces tumor protection.Moreover, depletion of CD4+ T cells in the priming phase results in a significant loss of tumor rejection (P = .02). BALB/c mice (n = 6) were vaccinated according to the immunization protocol outlined in Figure 4. Depletion of T cells was performed with injections of CD8.2 antibody during the effector phase (■, CD8-E) or with CD4.2 antibody during the immunization phase (⋄, CD4-I). Control mice (+) were not pretreated. All mice received an intravenous tumor challenge of 4 × 105 A20 cells. ▪ indicates bsAb. Peter Ruf, and Horst Lindhofer Blood 2001;98:2526-2534 ©2001 by American Society of Hematology

The postulated tri-cell complex model suggesting interactions that led to the induction of tumor immunity and improved tumor cell destruction by intact bsAb.The use of mouse IgG2a × rat IgG2b intact bsAb leads to the simultaneous recruitment of tumor cells,... The postulated tri-cell complex model suggesting interactions that led to the induction of tumor immunity and improved tumor cell destruction by intact bsAb.The use of mouse IgG2a × rat IgG2b intact bsAb leads to the simultaneous recruitment of tumor cells, T cells, and Fcγ-receptor+ accessory cells. The formation of this complex induces the activation of different classes of effector cells, resulting in excellent antitumor activity. The stimulation of accessory cells is demonstrated by the production of cytokines such as IL-1, IL-6, IL-12, and the DC-specific cytokine DC-CK1.5Activated accessory cells, particularly professional antigen-presenting cells such as DCs or activated macrophages mediate costimulatory signals, eg, via CD40-CD40L to T cells that are necessary to prevent T-cell anergy. Furthermore, tumor material is phagocytosed,14 processed, and presented by professional antigen-presenting cells after activation by bsAb—an important prerequisite for the induction of antitumor immunity. The tri-cell complex is only a model and should not implicate a 1:1:1 ratio of the 3 involved cell types. Peter Ruf, and Horst Lindhofer Blood 2001;98:2526-2534 ©2001 by American Society of Hematology